Julie Clark, M.D. is Adverum’s chief medical officer, responsible for clinical development strategy and execution. Over the course of her career, she has worked on clinical development programs and commercial launch initiatives for new therapies for ocular diseases, including Eylea
® and BEOVU
®. Previously, she worked with Novartis over a five-year period in positions of increasing responsibility. As lead medical director – retina, she was responsible for the Phase 3b clinical trial for BEOVU
® and served as medical lead for cross-functional team initiatives for product launch. Earlier, she was medical director, U.S. medical affairs for ThromboGenics, where she supported the Jetrea
® launch and late-stage clinical studies. Previously, she worked with Regeneron Pharmaceuticals, Inc., where as associate director, medical affairs – ophthalmology she supported the clinical development and commercial launch of Eylea
®. Before Regeneron, she worked with ISTA Pharmaceuticals as medical affairs product director and helped align strategy and communications for Xibrom
®/Bromday
®, Bepreve
®, Istalol
®, Vitrase
®. Dr. Clark earned an M.D. from Wake Forest University School of Medicine and a B.S. in Biology from Wake Forest University. In addition, she holds an M.S. in Biotechnology from the Center for Biotechnology Education and Advanced Biotechnology Studies from Johns Hopkins University.
How do I contact Julie Clark?
Has Julie Clark been buying or selling shares of Adverum Biotechnologies?
Julie Clark has not been actively trading shares of Adverum Biotechnologies during the last quarter. Most recently, Julie Clark sold 476 shares of the business's stock in a transaction on Thursday, September 30th. The shares were sold at an average price of $21.70, for a transaction totalling $10,329.20. Learn More on Julie Clark's trading history.
Who are Adverum Biotechnologies' active insiders?
Are insiders buying or selling shares of Adverum Biotechnologies?
During the last year, Adverum Biotechnologies insiders bought shares 1 times. They purchased a total of 10,000 shares worth more than $135,000.00. During the last year, insiders at the biotechnology company sold shares 1 times. They sold a total of 620 shares worth more than $9,424.00. The most recent insider tranaction occured on February, 7th when Director James Paul Scopa bought 10,000 shares worth more than $135,000.00. Insiders at Adverum Biotechnologies own 5.3% of the company.
Learn More about insider trades at Adverum Biotechnologies. Information on this page was last updated on 2/7/2024.
